Program
TQD3606
A development code. Also written as “The injectable TQD3606”.
In Sino Biopharmaceutical's pipeline, 美罗培南阿维巴坦钠
. Its studies are mostly in Infections, led by Sino Biopharmaceutical.
Furthest: phase 1, since Apr 1, 20222 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 20 open or running | phase 1since Apr 1, 2022 | Apr 1, 2022 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQD3606
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 1, 2022First study: phase 1 study in InfectionsFirst studyNCT05340530 · 56 enrolled · China
- Oct 31, 2024Phase 1 study in Resistant to Gram-positive, Gram-negative and Anaerobic BacteriaNCT06672276 · 32 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“美罗培南阿维巴坦钠”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06672276Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria · China | 1 | Completed | May 6, 2025 | 32 |
| NCT05340530Infections · China | 1 | UNKNOWN | Dec 2023 | 56 |
How it is read
Names in the registry
- “TQD3606”, 1 entry
- “The injectable TQD3606”, 1 entry
Codes read as this program: TQD3606.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.